Citi sets $86 price target on Cytokinetics stock with buy rating
Citi initiated coverage on Cytokinetics (NASDAQ:CYTK) with a Buy rating and an $86.00 price target, representing significant upside from the current price of $46.17. The firm's analysts highlighted ...
Pagaya upgraded to Buy at Citi as stage set for profit inflection
Pagaya Technologies (NASDAQ:PGY) stock surged 11% in Friday premarket trading after Citi upgraded the AI-powered lending software company to Buy from Neutral as the markdowns on some 2023 loans become ...